CERTAINTY
Financiado
A CEllulaR immunoTherapy virtuAl twin for personalIsed cancer treatmeNT
"This project aims to create a multi-scale patient-specific human virtual twin for patients who are eligible for CAR T cell therapy, which can be extended to cellular immunotherapies in general. The virtual twin will be fully inte...
"This project aims to create a multi-scale patient-specific human virtual twin for patients who are eligible for CAR T cell therapy, which can be extended to cellular immunotherapies in general. The virtual twin will be fully integrated into the ecosystem under the Digital Europe Programme and will be available as a research-use-only prototype in relevant application environments with technology readiness level 6. The virtual twin will support decision-making throughout the patient's journey, from diagnosis to pre-treatments, cellular immunotherapy, and late patient monitoring. This will enable patients and health experts to identify the most effective course of therapy.The virtual twin for cellular immunotherapies will take multi-scale modelling to the next level by providing methodological concepts for integrating ""living drugs"" such as CAR T cells into the human virtual twin ecosystem.To achieve this goal, the project builds on existing data models for hematological malignancies and multiple myeloma (MM) to create a virtual twin for CAR T cell therapy for MM patients. The implementation process follows software development principles for software as medical devices, ensuring the exploitation of the research-use-only prototype. Patient's, SSH, gender differences, and other stakeholders' perspectives are fully integrated into the design, specification, and implementation process.Throughout the implementation process, a modular software architecture and extensible ontologies/terminologies are utilized, making the reference model easily transferable to other indications that can be treated with CAR T cell therapy or other cellular immunotherapies. Overall, the CERTAINTY virtual twin will provide decision support for patients and health experts, improving the effectiveness of cellular immunotherapies and advancing precision medicine."
ver más
Duración del proyecto: 53 meses
Fecha Inicio: 2023-12-01
Fecha Fin: 2028-05-31
Fecha Fin: 2028-05-31
Línea de financiación: concedida
El organismo HORIZON EUROPE notifico la concesión del proyecto el día 2023-12-01
Línea de financiación objetivo
El proyecto se financió a través de la siguiente ayuda:
Presupuesto
El presupuesto total del proyecto asciende a
10M€
Líder del proyecto
FRAUNHOFER GESELLSCHAFT ZUR FORDERUNG DER ANG...
No se ha especificado una descripción o un objeto social para esta compañía.
Perfil tecnológico
TRL
4-5
Perfil tecnológico
TRL
4-5